title: Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders.
abstract: Public health can be protected most effectively through vaccination programmes. However, while presently available vaccination techniques protects the individual by provoking immune responses against exogenous antigens (ags), such as those associated with certain bacteria and viruses, they cannot protect against or treat mishaps caused by endogenous ag. Recently, Barabas and colleagues have developed a new vaccination method, called modified vaccination technique (MVT), which allows the presentation of disease causing agents in such a way as to initiate and maintain desired immune response outcomes even in the context of mishaps associated with endogenous ag. For example, in an experimental autoimmune kidney disease, the MVT downregulated/terminated pathogenic immune responses that were causing morphological and functional changes of the kidney. The MVT promises, with appropriate case-specific modifications, both preventative and curative applications for ailments, such as endogenous ag initiated mishaps (i.e. autoimmune diseases and cancer) and diseases caused by chronic infection, that are presently only treatable with drugs. To achieve specific immune responses, purified components of the vaccine (ag and antibodies) must be produced and assembled into immune complexes having the potential of inducing predetermined corrective immune response outcomes.
authors.affiliation: Department of Surgery, University of Calgary, Calgary, AB, Canada. barabas@ucalgary.ca
authors.forename: Arpad Z
authors.initials: AZ
authors.lastname: Barabas
authors.forename: Chad D
authors.initials: CD
authors.lastname: Cole
authors.forename: Arpad D
authors.initials: AD
authors.lastname: Barabas
authors.forename: Richard M
authors.initials: RM
authors.lastname: Graeff
authors.forename: Rene
authors.initials: R
authors.lastname: Lafreniere
authors.forename: Donald M
authors.initials: DM
authors.lastname: Weir
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D000936:Antigen-Antibody Complex / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D007674:Kidney Diseases / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D051381:Rats; D014611:Vaccination / Q000379:methods*
chemical_list: D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D019496:Cancer Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M